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Simple Summary: There are few publications on the subject of canine platelet concentrates and
further studies are required to characterize these for clinical applications. The aim of this study
determined platelet, erythrocyte, and leukocyte counts in canine leukocyte- and platelet rich plasma
(L-PRP) produced using a commercial semi-automated closed system (CPUNT 20, Eltek group, Casale
Monferrato, Alessandria, Italy). Whole blood (WB) from 30 healthy dogs was used. In 10 L-PRP bovine
thrombin activated samples platelet-derived growth factor isoform BB (PDGF-BB) concentration was
also measured. The CPUNT 20 produced clinically useful quantities of sterile canine L-PRP containing
a high concentration of platelets (767,633 ± 291,001 µL, p < 0.001), with a 4.4 fold increase in platelet
count, lower concentration of erythrocytes (528,600 ± 222,773 µL, p < 0.001) and similar concentration
of leukocytes (8422 ± 6346 µL, p = 0.9918) compared with WB. Neutrophils, lymphocytes and
monocytes average percent content in L-PRP was 14.8 ± 13.2, 71.7 ± 18.5 and 10.7 ± 6.4, respectively.
Activated L-PRP has an average of 3442 ± 2061 pg/mL of PDGF-BB.
Abstract: Background: To characterize the cellular composition (platelets, erythrocytes, and
leukocytes) and determine platelet-derived growth factor isoform BB (PDGF-BB) concentration
in canine leukocyte- and platelet rich plasma (L-PRP) produced using a commercial semi-automated
closed system. Methods: Twenty milliliters of citrated whole blood were obtained from 30 healthy
un-sedated canine blood donors and processed using a semi-automated completely closed
commercial system (CPUNT 20, Eltek group, Casale Monferrato, Alessandria, Italy) according
to the manufacturer’s instructions. Erythrocyte, leukocyte, and platelet counts were determined in
both whole blood (WB) and resultant L-PRP. The PDGF-BB concentration was evaluated after bovine
thrombin activation of 10 L-PRP samples. Results: This commercial system produced on average
2.3 ± 0.7 mL of L-PRP containing a high concentration of platelets (767,633 ± 291,001 µL, p < 0.001),
with a 4.4 fold increase in platelet count, lower concentration of erythrocytes (528,600 ± 222,773 µL,
p < 0.001) and similar concentration of leukocytes (8422 ± 6346 µL, p = 0.9918) compared with WB.
L-PRP had an average of 3442 ± 2061 pg/mL of PDGF-BB after thrombin activation. Neutrophils,
lymphocytes and monocytes average percent content in L-PRP was 14.8 ± 13.2, 71.7 ± 18.5 and
10.7 ± 6.4, respectively. Conclusion: Sterile canine L-PRP prepared using this semi-automated closed
system is easy to obtain, produces a significant increase in platelet count compared to WB and contains
a detectable concentration of PDGF-BB after activation. Additional in vitro and in vivo studies are
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needed to assess inflammatory markers concentration and the therapeutic efficacy of this L-PRP
in dogs.
Keywords: platelet-rich plasma; closed system; dog; platelet; growth factors; activation
1. Introduction
Platelet-rich plasma (PRP) is a product derived from whole blood, characterized by platelet
(PLT) concentrations higher than baseline in a small volume of plasma [1]. Growth factors such as
platelet-derived growth factor (PDGF), transforming growth factor beta, vascular endothelial growth
factor, basic fibroblastic growth factor, and epidermal growth factor usually contained in platelet α
granules are released when platelets are activated or destroyed [2,3]. The release of these growth factors,
that can act either individually or synergistically, into damaged tissue has the potential to facilitate cell
proliferation, angiogenesis, tendon and wound healing, production of fibroblasts, collagen, osteoblasts,
decreases the inflammatory reaction and accelerates the healing process [2,3]. The use of PRP for
delivery of growth factors has emerged as a convenient method for promoting wound healing and
tissue regeneration. The autologous nature of PRP preparations makes them safer and less expensive
than allogenic cell-based regenerative therapies. As a result, there is widespread use of PRP therapy in
human [4–9] and in veterinary medicine [10–21] prompting the need for development of simple and
reproducible methods for preparation of high-quality PRP for clinical use.
In human medicine various authors have tried to define simple parameters for assessing the
quality of platelet concentrates, a difficult target to achieve. Marx [22] has reported that the ideal PRP
should have a platelet count with a 3- to 5-fold increase over whole blood or an ideal concentration
of one million platelet/µL; similarly to Marx, Mazzucco [23] defines one million platelet/µL as a
“reasonable compromise” for a quality platelet concentrate for non-transfusion use, while 300,000
platelets/µL is described by Anitua [24] as the minimum platelet concentration needed in a quality PRP.
Platelet concentration is not the only important component of a PRP product; inclusion or exclusion
of leukocytes not only defines a platelet concentrate [25,26] but has also been reported to affect the
efficacy of the product and to have a significant effect on the inflammatory responses after clinical use
of PRP [27–32].
The collection and processing of PRP should preserve the platelets in a quiescent state so that
activation and subsequent growth factor release will be delayed until the moment of clinical use [33].
An important question is whether exogenous activation of PRP with thrombin or calcium should be
performed before clinical application: the use of non-activated PRP would result in a greater and longer
in time release of growth factors when the platelets are exposed to collagen and therefore activated in
the injured site, but this is difficult to confirm in vivo and activation at the lesion site may not occur
consistently [34–36]. The amount of growth factors available at the end of PRP production process
depends on the techniques used (from blood collection to centrifugation) [37–40], on the biological
variability of growth factor concentration among individuals [41,42] and on method of exogenous
activation [36], but the relationship between platelet and growth factors concentration is far from
clear [2,12,43].
Despite the popularity and advantages of PRP, there are conflicting reports in the literature
regarding its clinical efficacy [44–49]. These differences may, in part, be attributable to variations in the
composition of PRP preparations, therefore considerable research effort has been focused on optimizing
human [28,38,50–53] and equine [54–57] protocols with regard to reproducible recovery, yield and
cellular composition. However, there have been relatively fewer studies addressing optimization of
PRP protocols in dogs. Many different manual or semi-automated methods for PRP production in
dogs are described [58–61] achieving wide ranges of PLT concentration, but many of these studies
have been performed on a small number of subjects [58–60] and few studies provide information
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about concentrations of platelet-derived growth factor or p-selectin externalization when PRP is
activated [43,60,62–65]. Analysis of the previous studies indicates that it cannot be assumed that a
system will produce the same PRP from canine blood as that obtained from human blood. Furthermore,
the data highlight that the PRPs obtained by use of various commercially available systems can
potentially differ in their characteristics [63]. Characterization of PRP products with specific focus on
canine patients is needed to understand results of past, current, and future clinical applications or
in vivo experiments [59] and more detailed evaluations including the reproducibility in cell content,
growth factor concentration, and platelet activation status in the PRP have yet to be performed [63].
The aim of this study was to characterize the cellular composition (platelets, erythrocytes, and
leukocytes) and determine the platelet-derived growth factor-BB (PDGF-BB) concentration after
activation in the final product from a commercial semi-automated platelet-rich plasma closed system
using canine blood.
2. Materials and Methods
2.1. Subjects
After approval by the Ethics Committee of the University of Milan (protocol number 13-01-15)
and with owner-informed consent, citrated blood samples were collected from the cephalic vein of
30 healthy un-sedated adult canine blood donors (PLT count within the reference range), 17 males
and 13 females, weighing between 20 and 45 kg and between 2 and 8 years of age (mean ± standard
deviation: 4.2 ± 1.9 years). A variety of breeds were represented (e.g., Labrador retriever, Rhodesian
ridgeback, Corso dog) and all dogs were admitted to the Veterinary Transfusion Research Laboratory
(REVLab) of the Department of Veterinary Medicine for routine blood donor check-ups. All dogs were
fasted for 12 h before blood sample collection.
2.2. Samples Collection and PRP Production
A closed semi-automatic platelet-rich plasma (PRP) collection and producing system for veterinary
use (CPUNT 20, Eltek group, Casale Monferrato, Alessandria, Italy) was used, according to the
manufacturer’s instructions. Briefly, the system consists of a sterile, single use, disposable collection
kit for blood sampling, a dedicated centrifuge and an automatic instrument for the separation of the
PRP (Figure 1).
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The collection kit comprises a butterfly needle (19G) connected to a 20 mL syringe for blood
aspiration, with a port for anticoagulant addition and an antibacterial filter to preserve kit sterility,
and a 10 mL bag for the storage of the PRP (Figure 2). All three connections are equipped with plastic
clips that can be opened or closed as needed during the collection process. Two 10 mL syringes are also
supplied in the sterile package together with the collection kit. Before starting the collection procedure,
the three plastic clips (red, blue and green) must be closed, being careful to position the clip of the PRP
storage bag close to the bag itself.
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2.3. Platelet and Leukocyte Counts
For each test subject (30/30), platelet count (PLT/µL) leucocyte count ( B /µL) and erythrocyte
count (RB /µL), were calculated on WB and L-PRP by an automatic analyzer using optical
and volumetric impedance measurements (Cell-Dyn 3500 analyzer, Abbott Diagnostics Europe),
while neutrophils (cells/µL), monocytes (cells/µL) and lymphocytes (cells/µL) counts were calculated
with the same instrument and checked with a manual differential count of blood smears in only
19/30 subjects, for technical reasons. In the same 19 subjects the smears were also used for assessment
of possible platelet clumping. All sample were stored at room temperature on a laboratory blood
rocker for a minimu of 5 min before counts were performed.
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2.4. Microbiological Evaluation
This study was performed using a closed system designed to guarantee the sterility of the finished
product. However, having temporally disconnected the aspiration syringe from the storage bag to
withdraw 500 microliters of citrated WB for subsequent laboratory analysis (step not required by
the method) and still wanting to test the validity of the method for further possible clinical uses, we
performed bacteriological tests on seven, randomly chosen, L-PRP samples. One hundred microliters
of L-PRP was plated by streaking onto blood agar plates (Microbiol, Cagliari, Italy) both for aerobic
and anaerobic bacteria and then incubated at 35 ± 2 ◦C for at least 48 h [66].
2.5. Platelet Derived Growth Factor Evaluation
The PDGF-BB levels in 10 L-PRP samples were assessed after L-PRP activation of samples with.
bovine thrombin. To each 1 mL of L-PRP, 50 µL of a bovine thrombin solution (BioPharm Laboratories
LLC, Bluffdale, UT, USA) containing 500 IU/mL was added. After activation, the samples were kept
at 37 ◦C in an incubator. The supernatant (after spontaneous clot retraction) of each activated L-PRP
was collected at 3 h after activation and the concentration of PDGF-BB (pg/mL) was determined
using a human ELISA kit (Human PDGF-BB Duoset DY220E, R&D Systems, Minneapolis, MN, USA)
previously validated in dog [67] and used in others veterinary studies [41,68]. The mean detection
sensitivity was <15 pg/mL. Measurements of the concentrations of PDGF-BB were performed in
duplicate at 450 nm according to the manufacturer’s instructions.
2.6. Statistical Analysis
The normal distribution of parametric data was calculated using the D’Agostino-Pearson test and
only RBC and lymphocytes values were found to be normally distributed. Results are presented as
mean ± standard deviation. The statistical differences between mean values of PLT, WBC, neutrophils,
lymphocytes, monocytes and RBC on WB and L-PRP were compared using Wilcoxon rank sum test
or paired t-test depending on data distribution. The statistical differences between mean male and
female PLT values were compared using Mann-Whitney test. The increase in platelet concentration in
L-PRP over whole blood baseline values was calculated using the following equation: platelet count
L-PRP/platelet count WB. Spearman’s coefficient of rank correlation (rho) was used to evaluate the
relationship between cellular counts (PLT, WBC, neutrophils, lymphocytes, monocytes and RBC) in WB
and in L-PRP. Correlation between cellular (PLT, WBC, neutrophils, lymphocytes, monocytes and RBC)
and PDGF-BB concentrations in L-PRP were determined using Pearson test. For all tests significance
was set at p < 0.05. Statistical analyses were performed using commercial software (MedCalc Software
v.11.5.1 Mariakerke, Belgium).
3. Results
The mean volume of L-PRP obtained was 2.3 ± 0.7 mL. The average PLT, neutrophils, lymphocytes,
monocytes and RBC values comparing WB and L-PRP were significantly different (Table 1). There was
a 4.4-fold increase in the mean platelet concentration in L-PRP compared to baseline concentrations
in WB: the highest value of PLT concentration was 1,898,000/µL (9-fold increase), the lower value
was 304,000/µL (2-fold increased). There was no difference in L-PRP PLT concentration between
males and females (p = 0.44). The mean PDGF-BB concentration in L-PRP samples after thrombin
activation was 3442 ± 2061 pg/mL. Pearson correlation coefficient between cellular (PLT, WBC,
neutrophils, lymphocytes, monocytes and RBC) and PDGF concentrations in L-PRP were 0.62 (p = 0.05),
0.60 (p = 0.06), 0.43 (p = 0.22), 0.50 (p = 0.14), 0.88 (p = 0.0008) and 0.23 (p = 0.52), respectively.
All samples of L-PRP tested for bacteriological analysis were sterile.
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Table 1. Mean and standard deviation of whole blood (WB) and leukocyte-platelet rich plasma (L-PRP)
cell counts.
Cellular Type
(Number of Subject) WB (%) L-PRP (%)
p (◦ Wilcoxon;
* t-Test)
Spearman’s
Coefficient
Platelet (µL) (30/30) 185,300 ± 39,576 767,633 ± 291,001 <0.0001 ◦ rho: 0.259p: 0.1673
Leucocytes (µL) (30/30) 8167 ± 3425 8422 ± 6346 0.9918 ◦ rho: 0.387p: 0.034
Neutrophils (µL) (19/30) 6303 ± 3459 (63.7) 1250 ± 1960 (14.8) <0.0001 ◦ rho: 0.428p: 0.0762
Lymphocytes (µL) (19/30) 2500 ± 1329 (29.3) 5231 ± 2620 (71.7) 0.0001 * rho: 0.558p: 0.016
Monocytes (µL) (19/30) 248 ± 174 (3) 823 ± 792 (10.7) 0.0008 ◦ rho: −0.164p: 0.52
Erythrocytes (µL) (30/30) 5,907,433 ± 704,099 528,600 ± 222,773 <0.0001 * rho: −0.108p: 0.57
Legend: mean values of PLT, WBC, neutrophils, lymphocytes, monocytes and RBC on WB and L-PRP were compared
using Wilcoxon rank sum test (◦) or paired t-test (*) depending on data distribution. Spearman’s coefficient of
rank correlation (rho) was used to evaluate the relationship between platelet, leucocytes, neutrophils, lymphocytes,
monocytes and erythrocytes counts in WB and L-PRP.
4. Discussion
In this study canine L-PRP was prepared using a commercial semi-automated closed system.
All the steps of the production method were easy to perform and the volume of platelet concentrate
produced was more than sufficient (on average > 2 mL per subject were obtained) for therapeutic use:
PRP has been used in quantities ranging from 0.6 to 3 mL in a variety of canine pathologies [69–74].
The fact that the system is closed means the final product is free from bacterial contamination,
as confirmed by our microbiological evaluation This cannot be guaranteed in other double
centrifugation methods with the exception of a laminar flow chamber under sterile conditions
and with trained personnel. This is particularly important when canine platelet concentrates will be
used therapeutically [58,60]. The proven sterility makes CPUNT system ideal for using the platelet
concentrate for therapeutic regenerative purposes both in regions, such as joints or bone, that require a
perfect asepsis and in regions, such as the oral cavity or skin, where asepsis is less critical.
Interestingly, it is also possible to withdraw an aliquot of the L-PRP obtained from the collection
bag in a sterile manner, so as to be able to keep the remainder for dermatological or oculistic periodic
therapeutic treatments in the same subject. Shelf life of the remaining product may be prolonged
by freezing, as carried is out in human medicine [75,76], though studies demonstrate that freezing
is detrimental to platelet morphology and function and continuous synthesis of growth factors [36].
In veterinary medicine, there are few studies considering extension of the shelf life by freezing of
platelet concentrates [54,77–80] and in the dog there are no literature reports that confirm the best
preservation method. In fact, there is only one research study focused on growth factors evaluation
in which a small number of canine PRP samples was frozen at −80 ◦C and subsequently analyzed,
demonstrating an increase in the growth factors following freezing similar to that obtained with
calcium chloride activation [36] and one clinical study reporting PRP preservation (at −76 ◦C) before
application to skin wounds in the dog, with a subsequent excellent clinical response [15].
The system utilized demonstrated a consistent ability to enrich platelets in autologous plasma
(about fourfold) producing a significantly higher platelet count in L-PRP than in WB (p < 0.0001).
Traditionally, a three- to five-fold increase in platelets has been considered an appropriate concentration
for medical applications [22,51,57]. In this study, however, in 7 out of 30 samples the three times
target platelet increase was not reached, with increases in platelet numbers of between 2- and 2.8-fold.
No correlation was found between sex, age of the subjects, number of platelets in WB and L-PRP
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samples that did not reach the platelet target concentration. It is not uncommon in studies focused
on preparation of PRP in dog, for not all samples to reach the predetermined enrichment value,
with great variability between individual samples or very large reported standard deviations [13,58,81],
as happened also in our study in which the standard deviation for platelet concentration was large. In a
study on the assessment of a PRP produced with a commercial centrifugation and platelet recovery kit
the minimum platelet enrichment was still considered to be within an appropriate range for medical
application with 90% of samples falling within the range of 4.7- to 8.1-fold enrichment [63]. According to
previous literature [24], PRP products must achieve a platelet count of at least 300 × 103 platelets/µL to
be in the therapeutically effective range and this was reached by the seven sampled in this study that
failed to concentrate 4-fold. This proposed minimum platelet number for PRP has been extrapolated
from the human literature and key species differences in average platelet counts and platelet physiology
preclude an accurate evaluation of literature data [82]. The ideal enrichment of platelets in veterinary
PRP remains unknown and may depend on the species, the specific disease and the site of application
for the regenerative therapy. In man it has been shown that too many platelets may be detrimental
to tissue repair [25,30,31,57,83–85], but to date no studies have been conducted to investigate this in
dogs [59].
There was no statistical difference in L-PRP PLT concentration between the two sexes, but,
as already found in human patients and horses [41,42] as well as the dog the PLT count in P-PRP was
on average higher in females than males.
In our study, the L-PRP system utilized significantly decreased the RBC concentration compared
with WB (p < 0.001). Reducing RBC concentration is thought to be important when developing
the ideal PRP product [86]. A recent study revealed that an increased RBC concentration in PRP
increases the concentrations of unwanted inflammatory mediators, specifically IL-1 and TGF-α.
This study also showed that when synoviocytes are treated with RBC concentrate there were
significantly more synoviocyte deaths when compared with leukocyte-rich PRP, leukocyte-poor
PRP, and phosphate-buffered saline [86].
The CPUNT 20 separation instrument has two modes of use: the production mode of the PRP with
the inclusion of leukocytes, which allows L-PRP (leukocyte- and platelet-rich plasma) collection and
the production mode without the inclusion of leukocytes, which results in production of P-PRP (pure
platelet-rich plasma), according to Dohan Ehrenfest’s classification. In this study we used the PRP
production modality with the inclusion of leukocytes, obtaining an L-PRP with an average WBC not
statistically different from that in WB, with a moderate positive correlation between WBC concentration
in WB and L -PRP (rho = 0.387, p = 0.03). The average WBC in our L-PRP did not reach the limit of twice
baseline value defined by some authors [20,58] although the high standard deviation underlines a great
variability between the samples. Leukocyte concentrations may influence the effects of PRP therapy,
but their role is still a matter of debate. Leukocytes- and platelet-rich plasma has been associated with
increased pro-inflammatory mediators and a catabolic effect [29,87–89]. P-PRP has been thought to
be more beneficial than L-PRP in maintaining tendon homeostasis and counteracting inflammation
associated with osteoarthritis [27,31,86,89]. Interestingly, however, a human study found both groups
improved with no differences in pain or functional scores between P-PRP and L-PRP for intra-articular
knee injections [90]. Other authors have instead shown how the presence of leukocytes in an injectable
preparation of PRP can be useful for increasing the in situ production of growth factors [28,91], for the
potential analgesic effect through the release of different chemokines, anti-inflammatory cytokines
(IL-4, IL-10 and IL-13) and opioid peptides (β-endorphins, encephalins and dinorphine-A), to promote
the inhibition of pain in a clinically relevant way [26,92] and to increase the important antimicrobial
role in PRP [93,94].
In our study, in L-PRP we achieved a decrease in neutrophils and an increase in lymphocytes and
monocytes statistically significant compared to WB, with a positive correlation between lymphocytes
concentration in WB and L-PRP (rho = 0.558, p = 0.016). The potentially deleterious effects of leukocytes
are largely attributed to the presence of neutrophils [25,27,29,31], while the effect of monocytes
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and lymphocytes remains largely unknown. Further investigation is needed regarding various
leukocyte lineages, their concentrations, and their effects on PRP utilization evaluated according to
the purpose of use (e.g., regenerative, antimicrobial, analgesic). Based on the sparse canine literature
available it is already apparent that leukocyte profiles differ depending on the PRP processing method;
however further comparison of the current canine literature remains difficult until a standardized
methodology for assessing cellular enrichment or growth factor concentration is adopted for kit
analysis [63]. High WBC counts are generally accepted in platelet concentrates used for autologous
topical application [58,87,95]. Thus, the desirable WBC count is still a matter of speculation [25] and to
date there are no studies that clarify the significance of leukocytes in canine PRP and the optimal ratio
of platelet to leukocytes. Finally, the integrity of leukocytes seems to be of considerable importance:
centrifugation can activate or destroy white blood cells and/or stimulate the inflammatory state [26].
In our samples there was no any correlation in PLT count between WB and L-PRP when the
specific values for each L-PRP and WB samples were analyzed in line with previous studies in man [96],
but in contrast to what has been reported in the horse [54]. This conflicting result could depend on the
PRP production process used and/or on the different species evaluated and other studies are needed in
the dog to understand the validity of this lack of correlation.
The main objective for delivery of platelets is to increase growth factor concentrations to the
affected tissue; however platelet enrichment does not necessarily result in increased delivery of
growth factors since degranulation can occur during the centrifugation, leading to a plateau in
growth factors that depend on platelet activation [97]. The amount of growth factors available at
the end of PRP production process therefore depends on the particular technique used to obtain the
PRP [37,38,54,98,99]. However, the platelet growth factor concentrations in PRP could be influenced by
other methodological aspects, such as the type of anticoagulant used during blood collection, the ratio
of blood to anticoagulant, the type of activating agent and the activation protocol [32,34,36,43,53,68].
Among the numerous growth factors present in platelet α granules, we selected PDGF-BB as an index
of activated platelets because it is only secreted by activated platelets and is not found in plasma. Thus,
its concentration should represent platelets activation and alpha granules release [60]. In our study
the PDGF concentration in activated L-PRP is similar to that found in previous studies in dog [60,65],
demonstrating a correct release of growth factors following platelet activation with bovine thrombin.
The relevance of this to clinical application remains tenuous as in vivo activation depends on the site of
injection, and bovine thrombin cannot be used in vivo due to the potential for adverse immunological
reactions seen in human medicine [22,100]. Unfortunately, in our study the PDGF-BB dosage was
measured in only 10 samples and this may have affected our results on correlations with sex or breed,
which have previously been studied in man, horses and rabbits, with different results [41,96,101].
This study shows a positive and significative correlation between PDGF-BB concentration and
PLT concentration in L-PRP (Pearson index 0.62 with p = 0.005). The relationship between platelet and
PDGF concentrations is far from clear. Some authors report correlation between platelet and PDGF
concentrations [43,60] and others do not [12,37,42,64]. Franklin et al. [36] suggest that activation had
a greater effect on growth factor concentration than did cellular composition. Several factors might
contribute to these discordant results, for example: manipulation—induced platelet stress and variable
susceptibility of platelets to stress. Furthermore the biological variability of growth factor and platelet
concentration in PRP among individuals must be taken into account [41,42,96,102]. The presence
of a positive correlation between WBC and PDGF-BB and monocytes and PDGF in L-PRP (Pearson
index 0.6 with p = 0.06 and 0.88 with p = 0.0008, respectively) in our results seems to corroborate the
theory that the quantity of white blood cells in the PRP also influences the concentration of growth
factors [32,63,91].
A limitation of our study was that we did not measure PDGF-BB concentrations in whole blood.
We could speculate that the concentration of PDGF-BB might increase in L- PRP, after activation, in our
samples by comparing our values with those found in WB in the literature [65], but we cannot be
sure, also considering that the blood sampling site in the dog seems to affect the activation status
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of the platelets. [63] Further studies will be needed to investigate this. Another limitation was that
we did not measure whether platelets were fully activated in the L-PRP, perhaps with microscopical
morphological evaluation of blood smears or with p-selectin dosage [63,64]. Among the PRPs with the
same number of platelets, the concentrations of growth factors will depend on the number of activated
platelets [60] and there is a correlation between activated platelets and quantitative growth factors,
as reported in previous studies in canine PRP obtained with other methods [64]. To activate as many
platelets as possible, various agonists (collagen, ADP and thrombin, etc.) and the ratio between PRP
and agonist should be further studied in dogs, as suggested by previous authors [60].
Another limitation of our study was that we did not evaluate some key inflammatory markers,
such as interleukin—1β or TNF-α, and their correlation with WBC and PLT content in L-PRP.
The concentration of these catabolic cytokines, that seems differ in various PRPs, may be clinically
relevant. A final limitation was that we didn’t evaluate the production mode without the inclusion of
leukocytes of the CPUNT 20 separation instrument, which results in production of P-PRP, according to
the manufacturer’s instructions; it would have been interesting to compare the characteristics of the
two options provided by the kit with canine samples.
5. Conclusions
The closed semi-automated system utilized in this study produced a fourfold mean increase
in platelets, but with a large standard deviation and reduced the relative percentage recovery of
erythrocytes, with a similar concentration of leukocytes but with a lower concentration of neutrophils
as in baseline WB. The autologous L-PRP obtained had PDGF-BB concentration comparable to previous
data in the literature after activation with bovine thrombin, was sterile and was produced in a sufficient
volume to allow clinical use in various fields of canine medicine. Further studies are recommended to
evaluate inflammatory markers and clinical application of this L-PRP product in dogs.
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